AR101597A1 - Proteínas de fusión uti (inhibidor de tripsina urinaria) - Google Patents
Proteínas de fusión uti (inhibidor de tripsina urinaria)Info
- Publication number
- AR101597A1 AR101597A1 ARP150102677A ARP150102677A AR101597A1 AR 101597 A1 AR101597 A1 AR 101597A1 AR P150102677 A ARP150102677 A AR P150102677A AR P150102677 A ARP150102677 A AR P150102677A AR 101597 A1 AR101597 A1 AR 101597A1
- Authority
- AR
- Argentina
- Prior art keywords
- uti
- fusion protein
- uti fusion
- tripsine
- urinary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461943617P | 2014-02-24 | 2014-02-24 | |
| PCT/US2015/017152 WO2015127391A1 (en) | 2014-02-24 | 2015-02-23 | Uti fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101597A1 true AR101597A1 (es) | 2016-12-28 |
Family
ID=52629709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102677A AR101597A1 (es) | 2014-02-24 | 2015-08-20 | Proteínas de fusión uti (inhibidor de tripsina urinaria) |
Country Status (38)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA39347B2 (fr) * | 2014-02-24 | 2020-05-29 | Takeda Pharmaceuticals Co | Protéines de fusion d'uti |
| KR20250030036A (ko) * | 2017-06-07 | 2025-03-05 | 스파크 테라퓨틱스, 인코포레이티드 | 개선된 세포 트랜스펙션 및/또는 rAAV 벡터 생산을 위한 증진제 |
| WO2020106881A1 (en) * | 2018-11-20 | 2020-05-28 | Diamedica Inc. | Modified ulinastatin polypeptides |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| BR112022017718A2 (pt) * | 2020-03-05 | 2022-11-16 | Diamedica Usa Inc | Polipeptídeos de ulinastatina |
| JP2024505073A (ja) * | 2021-01-29 | 2024-02-02 | ダイアメディカ ユーエスエー インコーポレイテッド | 疾患を処置するためのウリナスタチンポリペプチド |
| CN116903721A (zh) * | 2023-06-16 | 2023-10-20 | 成都佩德生物医药有限公司 | 多肽pdbpe-001、其药物组合物和用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| ES2066033T3 (es) | 1989-05-13 | 1995-03-01 | Bayer Ag | Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. |
| CA2055425A1 (en) | 1990-11-13 | 1992-05-14 | Hideaki Morishita | Polypeptide, dna fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same |
| JP2769083B2 (ja) | 1993-02-22 | 1998-06-25 | 日清食品株式会社 | エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法 |
| WO1997033996A2 (en) | 1996-03-11 | 1997-09-18 | Bayer Corporation | Human bikunin |
| DE19725014A1 (de) | 1997-06-13 | 1998-12-17 | Bayer Ag | Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten |
| SI1730191T1 (sl) * | 2004-03-30 | 2011-11-30 | Glaxo Group Ltd | Imunoglobulin-vezavni hOSM |
| CA2578613A1 (en) | 2004-08-11 | 2007-01-25 | Trubion Pharmaceuticals, Inc. | Binding domain fusion proteins |
| WO2006129849A1 (ja) * | 2005-06-03 | 2006-12-07 | Mochida Pharmaceutical Co., Ltd. | 抗ｃｄ１４抗体融合蛋白質 |
| US8828703B2 (en) | 2005-12-29 | 2014-09-09 | Dyax Corp. | Protease inhibition |
| WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| CN102580085B (zh) * | 2008-10-13 | 2013-09-18 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗脓毒症药物中的应用 |
| CN101721699B (zh) * | 2008-10-13 | 2012-11-07 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备治疗伴随vegf升高的炎症反应的药物中的应用 |
| US20120052069A1 (en) * | 2009-05-05 | 2012-03-01 | Amgen Inc | Fgf21 mutants and uses thereof |
| PL3053932T3 (pl) * | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| PH12013502441B1 (en) * | 2011-04-29 | 2019-02-08 | Univ Washington | Therapeutic nuclease compositions and methods |
| US8619331B2 (en) | 2011-07-19 | 2013-12-31 | Xerox Corporation | Simulated paper texture using clear toner and glossmark on texture-less stock |
| JP6138815B2 (ja) * | 2011-12-01 | 2017-05-31 | エーピー バイオサイエンシーズ， インコーポレイテッド | 補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法 |
| WO2013162050A1 (ja) * | 2012-04-23 | 2013-10-31 | 株式会社Ｎｒｌファーマ | ラクトフェリン融合タンパク質及びその製造方法 |
| JP2013253079A (ja) * | 2012-05-14 | 2013-12-19 | Xuhua (Shanghai) Biological Research & Development Center Co Ltd | 生物学的に活性なヒト尿中トリプシンインヒビターのＦｃ融合タンパク質並びにその調製および使用 |
| CN103044554B (zh) | 2012-05-14 | 2014-08-27 | 旭华（上海）生物研发中心有限公司 | 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用 |
| MA39347B2 (fr) * | 2014-02-24 | 2020-05-29 | Takeda Pharmaceuticals Co | Protéines de fusion d'uti |
-
2015
- 2015-02-23 MA MA39347A patent/MA39347B2/fr unknown
- 2015-02-23 SI SI201530516T patent/SI3110434T1/sl unknown
- 2015-02-23 AU AU2015218704A patent/AU2015218704B2/en active Active
- 2015-02-23 EP EP18192690.8A patent/EP3443978A1/en not_active Withdrawn
- 2015-02-23 PT PT15708411T patent/PT3110434T/pt unknown
- 2015-02-23 NZ NZ724196A patent/NZ724196A/en unknown
- 2015-02-23 US US15/120,956 patent/US9856310B2/en active Active
- 2015-02-23 NZ NZ760789A patent/NZ760789A/en unknown
- 2015-02-23 EA EA202091567A patent/EA202091567A1/ru unknown
- 2015-02-23 KR KR1020167026429A patent/KR102461210B1/ko active Active
- 2015-02-23 DK DK15708411.2T patent/DK3110434T3/en active
- 2015-02-23 PH PH1/2016/501629A patent/PH12016501629B1/en unknown
- 2015-02-23 UA UAA201609101A patent/UA118866C2/uk unknown
- 2015-02-23 CN CN201580014645.3A patent/CN106232135B/zh active Active
- 2015-02-23 MX MX2016010950A patent/MX2016010950A/es active IP Right Grant
- 2015-02-23 EA EA201691702A patent/EA037256B1/ru unknown
- 2015-02-23 SG SG11201606691QA patent/SG11201606691QA/en unknown
- 2015-02-23 NZ NZ760008A patent/NZ760008A/en unknown
- 2015-02-23 RS RS20181514A patent/RS58285B1/sr unknown
- 2015-02-23 LT LTEP15708411.2T patent/LT3110434T/lt unknown
- 2015-02-23 JP JP2016553562A patent/JP6574431B2/ja active Active
- 2015-02-23 MX MX2020000537A patent/MX384070B/es unknown
- 2015-02-23 EP EP15708411.2A patent/EP3110434B1/en active Active
- 2015-02-23 WO PCT/US2015/017152 patent/WO2015127391A1/en not_active Ceased
- 2015-02-23 GE GEAP201814277A patent/GEAP201814277A/en unknown
- 2015-02-23 MY MYPI2016703046A patent/MY178774A/en unknown
- 2015-02-23 BR BR112016019390-3A patent/BR112016019390B1/pt active IP Right Grant
- 2015-02-23 PL PL15708411T patent/PL3110434T3/pl unknown
- 2015-02-23 ES ES15708411T patent/ES2700149T3/es active Active
- 2015-02-23 CN CN201910282497.3A patent/CN110092837B/zh active Active
- 2015-02-23 HR HRP20182029TT patent/HRP20182029T1/hr unknown
- 2015-02-23 PE PE2016001522A patent/PE20170257A1/es unknown
- 2015-02-23 CR CR20160444A patent/CR20160444A/es unknown
- 2015-02-23 KR KR1020227037377A patent/KR102722304B1/ko active Active
- 2015-02-23 SG SG10201708400QA patent/SG10201708400QA/en unknown
- 2015-02-23 KR KR1020247035230A patent/KR20240155987A/ko active Pending
- 2015-02-23 SM SM20180674T patent/SMT201800674T1/it unknown
- 2015-02-23 GE GEAP201514277A patent/GEP20196970B/en unknown
- 2015-02-23 CA CA2939639A patent/CA2939639C/en active Active
- 2015-02-23 CA CA3178241A patent/CA3178241A1/en active Pending
- 2015-08-20 JO JOP/2015/0200A patent/JO3729B1/ar active
- 2015-08-20 AR ARP150102677A patent/AR101597A1/es unknown
- 2015-08-21 TW TW104127393A patent/TWI694084B/zh active
-
2016
- 2016-08-10 DO DO2016000202A patent/DOP2016000202A/es unknown
- 2016-08-17 IL IL247321A patent/IL247321B/en active IP Right Grant
- 2016-08-23 MX MX2024000004A patent/MX2024000004A/es unknown
- 2016-08-23 MX MX2019013124A patent/MX2019013124A/es unknown
- 2016-08-24 CL CL2016002136A patent/CL2016002136A1/es unknown
- 2016-09-13 ZA ZA2016/06327A patent/ZA201606327B/en unknown
- 2016-09-23 EC ECIEPI201676535A patent/ECSP16076535A/es unknown
-
2017
- 2017-11-27 US US15/823,398 patent/US10351618B2/en active Active
-
2018
- 2018-12-18 CY CY181101355T patent/CY1120997T1/el unknown
-
2019
- 2019-02-15 US US16/277,606 patent/US20200040062A1/en not_active Abandoned
- 2019-06-11 JP JP2019109054A patent/JP6938565B2/ja active Active
- 2019-06-25 AU AU2019204448A patent/AU2019204448B2/en active Active
-
2021
- 2021-06-03 US US17/337,922 patent/US20220127334A1/en not_active Abandoned
- 2021-08-31 AU AU2021225156A patent/AU2021225156B2/en active Active
- 2021-09-01 JP JP2021142544A patent/JP2022002513A/ja active Pending
-
2023
- 2023-02-16 AU AU2023200875A patent/AU2023200875A1/en not_active Abandoned
- 2023-06-30 JP JP2023108024A patent/JP2023123763A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
| MX2025003310A (es) | Integracion dirigida de acidos nucleicos | |
| MX2021014007A (es) | Proteinas de union a epcam y metodos de uso. | |
| SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
| DOP2018000245A (es) | Proteinas de fusion gdf15 y usos de estas | |
| EA201991409A3 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
| MX391136B (es) | FRAGMENTOS DE OspA ESTABILIZADOS CON CISTEÍNA Y MÉTODO DE USO | |
| PH12016500239A1 (en) | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof | |
| PH12019500440A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| CL2021002168A1 (es) | Péptido asociado a tumor; ácido nucleico; vector de expresión; célula huésped recombinante; método para producir el péptido; linfocitos t activados y su método de producción; anticuerpo; tcr; uso para tratar el cáncer; kit y composición farmacéutica; método para producir vacuna; y áptaro (divisional solicitud no. 201702407). | |
| AR083740A1 (es) | Anticuerpos dkk1 (dickkopf-1) y metodos de uso | |
| PH12013501865A1 (en) | Potent and selective inhibitors of nav1.3 and nav1.7 | |
| EP4311857A3 (en) | Recombinant host cell engineered to overexpress helper proteins | |
| EA201390156A1 (ru) | ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ | |
| EA201691095A1 (ru) | Мутантные фрагменты ospa и связанные с ними способы и применение | |
| MX384070B (es) | Proteínas de fusión de inhibidor de tripsina urinaria (uti). | |
| EP4406969A3 (en) | Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients | |
| WO2022103929A3 (en) | Nucleic acids, proteins, and vaccines of sars-cov-2 | |
| EP3925968A3 (en) | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell | |
| AR100824A1 (es) | Complejo de poliproteínas inmunogénicas de m. hyopneumoniae, gen sintético codificante del complejo de proliproteínas inmunogénicas de m. hyopneumoniae, composición antigénica, proceso de obtención de un complejo de poliproteínas inmunogénicas de m. hyopneumoniae, uso de una composición con base en el complejo de poliproteínas inmunogénicas de m. hyopneumoniae | |
| ZA202201468B (en) | Method | |
| WO2015200768A3 (en) | Pharmacologic treatments of menière's disease | |
| CO2019000942A2 (es) | Composición y uso de un péptido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |